PD‐1/PD‐L1 immune checkpoint: Potential target for cancer therapy

• Published in: Journal of cellular physiology Vol. 234; no. 2; pp. 1313 - 1325
• Main Authors: Dermani, Fatemeh K., Samadi, Pouria, Rahmani, Golebagh, Kohlan, Alisa K., Najafi, Rezvan
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 01.02.2019
• Subjects: Animals; Anticancer properties; Antineoplastic Agents, Immunological - adverse effects; Antineoplastic Agents, Immunological - therapeutic use; Antitumor activity; Apoptosis; B7-H1 Antigen - antagonists & inhibitors; B7-H1 Antigen - immunology; B7-H1 Antigen - metabolism; Cancer; Cancer therapies; Cell death; Dendritic cells; Humans; Immune checkpoint; immune checkpoints; Immunity; Immunotherapy - adverse effects; Immunotherapy - methods; Ligands; Lymphocytes; Lymphocytes B; Lymphocytes T; Molecular Targeted Therapy; Natural killer cells; Neoplasms - drug therapy; Neoplasms - immunology; Neoplasms - metabolism; Neoplasms - pathology; PD-L1 protein; Programmed Cell Death 1 Receptor - antagonists & inhibitors; Programmed Cell Death 1 Receptor - immunology; Programmed Cell Death 1 Receptor - metabolism; programmed cell death protein 1 (PD‐1); programmed death ligand 1 (PD‐L1); Proteins; Signal Transduction; Treatment Outcome; Tumor cells; Tumor Escape; Tumor Microenvironment; Tumors; cancer; programmed death ligand 1 (PD-L1); programmed cell death protein 1 (PD-1); immune checkpoints
• DOI: 10.1002/jcp.27172
• ISSN: 0021-9541; 1097-4652

Recent studies show that cancer cells are sometimes able to evade the host immunity in the tumor microenvironment. Cancer cells can express high levels of immune inhibitory signaling proteins. One of the most critical checkpoint pathways in this system is a tumor‐induced immune suppression (immune checkpoint) mediated by the programmed cell death protein 1 (PD‐1) and its ligand, programmed death ligand 1 (PD‐L1). PD‐1 is highly expressed by activated T cells, B cells, dendritic cells, and natural killer cells, whereas PD‐L1 is expressed on several types of tumor cells. Many studies have shown that blocking the interaction between PD‐1 and PD‐L1 enhances the T‐cell response and mediates antitumor activity. In this review, we highlight a brief overview of the molecular and biochemical events that are regulated by the PD‐1 and PD‐L1 interaction in various cancers. In this review, we highlight a brief overview of the molecular and biochemical events that are regulated by the PD‐1 and PD‐L1 interaction in various cancers.